The anorexigenic effects of metformin involve increases in hypothalamic leptin receptor expression

Metabolism: Clinical and Experimental

Volumn 60, Issue 3, 2011, Pages 327-334

  Aubert, Grégory ^a   Mansuy, Virginie ^a   Voirol, Marie Jeanne ^a   Pellerin, Luc ^a   Pralong, François P ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; LEPTIN; LEPTIN RECEPTOR; METFORMIN; NEUROPEPTIDE Y;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARCUATE NUCLEUS; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENERGY; FEEDING; FOOD INTAKE; GENE EXPRESSION; HYPOTHALAMUS; IN VIVO STUDY; LONG EVANS RAT; MALE; METABOLISM; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR GENE; WEIGHT REDUCTION;

AGOUTI-RELATED PROTEIN; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; EATING; HUMANS; HYPOGLYCEMIC AGENTS; HYPOTHALAMUS; INSULIN; LEPTIN; MALE; METFORMIN; NEUROPEPTIDE Y; OBESITY; PRO-OPIOMELANOCORTIN; RANDOM ALLOCATION; RATS; RATS, LONG-EVANS; RECEPTORS, LEPTIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; STATISTICS, NONPARAMETRIC;

EID: 79951783938     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2010.02.007     Document Type: Article

References (27)

1. Cowley MA, Smart JL, Rubinstein M, Cerdan MG, Diano S, Horvath TL, Cone RD, Low MJ. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature 2001;411:480-4. (Pubitemid 32494394)
2. Elias CF, Kelly JF, Lee CE, Ahima RS, Drucker DJ, Saper CB, Elmquist JK. Chemical characterization of leptin-activated neurons in the rat brain. J Comp Neurol 2000;423:261-81. (Pubitemid 30421790)
3. Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW. Central nervous system control of food intake and body weight. Nature 2006;443:289-95. (Pubitemid 44435142)
4. Huang XF, Han M, Storlien LH. The level of NPY receptor mRNA expression in diet-induced obese and resistant mice. Brain Res Mol Brain Res 2003;115:21-8. (Pubitemid 36725032)
5. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002;137:25-33. (Pubitemid 34705373)
6. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43. (Pubitemid 44903747)
7. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:550-4.
8. Glueck CJ, Fontaine RN, Wang P, Subbiah MT, Weber K, Illig E, Streicher P, Sieve-Smith L, Tracy TM, Lang JE, McCullough P. Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Metabolism 2001;50:856-61. (Pubitemid 32700469)
9. Kim YW, Kim JY, Park YH, Park SY, Won KC, Choi KH, Huh JY, Moon KH. Metformin restores leptin sensitivity in high-fat-fed obese rats with leptin resistance. Diabetes 2006;55:716-24.
10. Chau-Van C, Gamba M, Salvi R, Gaillard RC, Pralong FP. Metformin inhibits adenosine 5′-monophosphate-activated kinase activation and prevents increases in neuropeptide Y expression in cultured hypothalamic neurons. Endocrinology 2007;148:507-11. (Pubitemid 46143156)
11. Minokoshi Y, Alquier T, Furukawa N, Kim YB, Lee A, Xue B, Mu J, Foufelle F, Ferre P, Birnbaum MJ, Stuck BJ, Kahn BB. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 2004;428:569-74. (Pubitemid 38480541)
12. Kola B, Hubina E, Tucci SA, Kirkham TC, Garcia EA, Mitchell SE, Williams LM, Hawley SA, Hardie DG, Grossman AB, Korbonits M. Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. J Biol Chem 2005;280:25196-201. (Pubitemid 40934612)
13. Stanley BG, Kyrkouli SE, Lampert S, Leibowitz SF. Neuropeptide Y chronically injected into the hypothalamus: a powerful neurochemical inducer of hyperphagia and obesity. Peptides 1986;7:1189-92. (Pubitemid 17226746)
14. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167-74. (Pubitemid 32995375)
15. Beckmann R. Absorption, distribution in the organism and elimination of metformin. Diabetologia 1969;5:318-24.
16. Levin BE, Dunn-Meynell AA, Balkan B, Keesey RE. Selective breeding for diet-induced obesity and resistance in Sprague-Dawley rats. Am J Physiol 1997;273:R725-R730.
17. Munzberg H, Flier JS, Bjorbaek C. Region-specific leptin resistance within the hypothalamus of diet-induced obese mice. Endocrinology 2004;145:4880-9. (Pubitemid 39551104)
18. Gao J,GhibaudiL, van HeekM,Hwa JJ. Characterization of diet-induced obese rats that develop persistent obesity after 6 months of high-fat followed by 1 month of low-fat diet. Brain Res 2002;936:87-90.
19. Harrold JA, Williams G, Widdowson PS. Changes in hypothalamic agouti-related protein (AGRP), but not alpha-MSH or pro-opiomelanocortin concentrations in dietary-obese and food-restricted rats. Biochem Biophys Res Commun 1999;258:574-7. (Pubitemid 29290310)
20. Parekh PI, Petro AE, Tiller JM, Feinglos MN, Surwit RS. Reversal of diet-induced obesity and diabetes in C57BL/6J mice. Metabolism 1998;47:1089-96. (Pubitemid 28428014)
21. Levin BE, Dunn-Meynell AA. Defense of body weight depends on dietary composition and palatability in rats with diet-induced obesity. Am J Physiol Regul Integr Comp Physiol 2002;282:R46-54.
22. Rouru J, Huupponen R, Pesonen U, Koulu M. Subchronic treatment with metformin produces anorectic effect and reduces hyperinsulinemia in genetically obese Zucker rats. Life Sci 1992;50:1813-20.
23. Bailey CJ, Flatt PR, Ewan C. Anorectic effect of metformin in lean and genetically obese hyperglycaemic (ob/ob) mice. Arch Int Pharmacodyn Ther 1986;282:233-9. (Pubitemid 16036952)
24. Golay A. Metformin and body weight. Int J Obes (Lond) 2008;32:61-72.
25. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005;65:385-411. (Pubitemid 40227460)
26. Steinberg GR, McAinch AJ, Chen MB, O'Brien PE, Dixon JB, Cameron-Smith D, Kemp BE. The suppressor of cytokine signaling 3 inhibits leptin activation of AMP-kinase in cultured skeletal muscle of obese humans. J Clin Endocrinol Metab 2006;91:3592-7. (Pubitemid 44402142)
27. WulffeleMG,KooyA, Lehert P,BetsD,Ogterop JC,Borger van derBurg B, Donker AJ, Stehouwer CD. Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care 2002;25:2133-40.